1905 SBMA patients monitored for up to 8 years on leuprorelin

This study looked at the long-term safety and effectiveness of the drug leuprorelin in 1,905 people with spinal and bulbar muscular atrophy (SBMA), a rare muscle-weakening disease. Participants were followed for up to 8 years in routine medical care. The main goals were to track side effects and serious health events, and to see how many people survived or avoided pneumonia serious enough to require hospital care.